<DOC>
	<DOCNO>NCT00736099</DOCNO>
	<brief_summary>The objective current study investigate safety tolerability BI 1356 ( 5 mg / daily ) give 78 week different modality treatment . The treatment modality determine treatment blind trial every patient include previously BI 1356 monotherapy ( patient 1218.16 trial ) , BI 1356 combination pioglitazone ( patient 1218.15 trial ) , BI 1356 add metformin background ( patient 1218.17 trial ) BI 1356 add background therapy metformin combination sulphonylurea ( patient 1218.18 study )</brief_summary>
	<brief_title>Safety Efficacy Linagliptin ( BI 1356 ) Monotherapy Combination Type 2 DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed date write informed consent accordance GCP local legislation . 2 . Patients complete entire treatment period double blind trial whether treat rescue medication . Exclusion criterion : 1 . Patients meet one withdrawal criterion treatment period previous trial . 2 . Premenopausal woman ( last menstruation = &lt; 1 year prior sign informed consent ) : nursing pregnant , childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intra uterine devices/systems ( IUDs/IUSs ) , oral , implantable injectable contraceptive , true sexual abstinence ( line prefer usual lifestyle patient ; periodic abstinence [ e.g . calendar , ovulation , symptothermal , postovulation method ] withdrawal acceptable method birth control ) vasectomise partner . No exception make . 3 . Alcohol abuse within 3 month prior inform consent would interfere trial participation . 4 . Drug abuse , opinion investigator , would interfere trial participation . 5 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>